 7. In the absence of rapidly progressing disease, the interval from prior treatment to time of initiation of FLX925 administration will be 2 weeks for cytotoxic agents and 5 half-lives for investigationalnon-cytotoxic agents. For patients with rapidly proliferative disease, use of hydroxyurea is allowed if started prior to initiation of study therapy; 